Cisco CFO: Services...
Health Care: Drugs
Ariad Pharmaceuticals (ARIA: NASDAQ)
$16.62 -0.05 | -0.30%
05/20/13 - 12:30 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 558.00K | 25.30M | 178.98M | 8.30M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 558.00K | 25.30M | 178.98M | 8.30M |
| Selling, General, and Administrative Expenses | 60.91M | 24.38M | 16.10M | 16.89M |
| Research & Development | 144.71M | 77.74M | 57.98M | 63.45M |
| Operating Income before D & A (EBITDA) | -205.06M | -76.82M | 104.90M | -72.03M |
| Depreciation & Amortization | 8.31M | 4.61M | 6.15M | 4.22M |
| Interest Income | 240.00K | 167.00K | 86.00K | 116.00K |
| Other Income - Net | -15.85M | -46.72M | -19.53M | -7.80M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -228.98M | -127.98M | 79.31M | -83.94M |
| Interest Expense | 199.00K | 232.00K | 206.00K | 287.00K |
| Pre-Tax Income | -229.18M | -128.22M | 79.10M | -84.23M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -220.87M | -123.60M | 85.25M | -80.01M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -220.87M | -123.60M | 85.25M | -80.01M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -220.87M | -123.60M | 85.25M | -80.01M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-220.87M | -123.60M | 85.25M | -80.01M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -220.87M | -123.60M | 85.25M | -80.01M |
| Basic EPS from Continuing Ops. | -1.34 | -0.93 | 0.75 | -0.86 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.34 | -0.93 | 0.75 | -0.86 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.34 | -0.93 | 0.75 | -0.86 |
| Basic Normalized Net Income/Share | -1.34 | -0.93 | 0.75 | -0.86 |
| EPS fr Continuing Ops. | -1.34 | -0.93 | 0.74 | -0.86 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.34 | -0.93 | 0.74 | -0.86 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.34 | -0.93 | 0.74 | -0.86 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.34 | -0.93 | 0.74 | -0.86 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARIA
- Portfolio NameUser Type
- ProSteven Cohen - SAC Capital
- ProDaniel Loeb - Third Point
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Rising On Unusual Vo...
Latest ARIA Headlines from TheStreet
- Ariad Stock Falls On Unusually High Volume (ARIA) 05.16.13 | 12:05 pm
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
- Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech 04.05.13 | 07:04 am
- Ariad CEO Strikes Back, Insists Leukemia Drug Is Fine 04.04.13 | 10:04 am
- Ariad Stock Falls On Unusually High Volume (ARIA) 04.03.13 | 02:04 pm
- The Survey Says: Ariad's Leukemia Drug Is Toxic 04.03.13 | 01:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- Ariad Pharmaceuticals (ARIA): Drugs' Highlighted Dud Of The Day 03.28.13 | 05:03 pm
- Ariad Pharma Falls On Weak Leukemia Drug Prescriptions 03.27.13 | 12:03 pm
- Ariad Stock Falls On Unusually High Volume (ARIA) 03.25.13 | 04:03 pm
Press Releases for ARIA
- ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion For Approval In The European Union - Business Wire 03.22.13 | 08:03 am
- ARIAD Announces Presentations Of Preclinical Data At American Association For Cancer Research Annual Meeting - Business Wire 03.20.13 | 07:03 am
- ARIAD To Present At Barclays Global Healthcare Conference - Business Wire 03.06.13 | 07:03 am
- ARIAD To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.28.13 | 07:02 am
- ARIAD Reports 2012 Financial Results And Outlines Key Objectives For 2013 - Business Wire 02.25.13 | 07:02 am
- Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl (Photo: Business Wire) - Business Wire 02.21.13 | 02:02 am
- ARIAD To Present At The RBC Capital Markets Healthcare Conference - Business Wire 02.19.13 | 07:02 am
- ARIAD To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.08.13 | 07:02 am
- ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2012 Financial Results - Business Wire 02.05.13 | 07:02 am
- ARIAD Announces Completion Of Public Offering - Business Wire 01.29.13 | 04:01 pm
Partner Headlines for ARIA
- Pre-Market Earnings Report for February 25, 2013 : LOW, FE, HTZ, DCI, KOS, ARIA, DDD, BGC, CTB, CWH, HL, DNDN - NASDAQ 02.22.13 | 09:02 pm
- Mid-Week Biopharma Catalyst Trades To Consider - Seeking Alpha 12.13.12 | 09:12 am
- UPDATE: Dawson James Initiates Coverage on Ariad Pharmaceuticals with Market Outperform Rating, $32 PT - Benzinga 12.07.12 | 09:12 am
- Data Published on ARIAD Candidate - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- ARIAD Seeks Ponatinib Approval - Analyst Blog - Zacks 10.02.12 | 06:10 pm
- ARIAD Partner Withdraws PMA - Analyst Blog - NASDAQ 09.19.12 | 08:09 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - NASDAQ 08.31.12 | 10:08 pm
- ARIAD Seeks EU Nod for Ponatinib - Analyst Blog - Zacks 08.31.12 | 06:08 pm
